Noteworthy Documents

Search all documents

Recently Added Publications

Title Published Date Office File(s) Page
Procurement - Summary of Purchase Orders Controller Summary Report: 9-1-2015 thru 4-23-2019 More Info on Procurement - Summary of Purchase Orders
RFQ Response Worksheet General Counsel RFQ Response Worksheet 2019--2021 More Info on RFQ Response Worksheet
Memorandum of Understanding-Investment Related Transactions & Account: FY 2019 Controller March 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
More Info on Memorandum of Understanding-Investment Related Transactions & Account: FY 2019
Real Estate Office - Organizational Chart Real Estate REO Organizational Chart 4.15.2019 More Info on Real Estate Office - Organizational Chart
AbbVie Inc. General Counsel AbbVie Master Clinical Study Agreement (Sponsor Initiated; Includes StemCentrx as an Affiliate; Effective Date October 20, 2016)
AbbVie Master Confidential Disclosure Agreement (for benefit of Clinical Trials Xpress); Effective 5/1/2018 - 03/31/2023
More Info on AbbVie Inc.
Annual Eligibility Notice for Retirement Plans Employee Benefits Annual Eligibility Notice for Retirement Plans More Info on Annual Eligibility Notice for Retirement Plans
Monthly Financial Report: FY 2019 Controller Feb 2019
Jan 2019
Dec 2018
Nov 2018
More Info on Monthly Financial Report: FY 2019
Novartis Pharmaceuticals Corporation- Master Clinical Trial Agreements General Counsel Novartis Pharmaceuticals Corporation - Master Clinical Trial Agreement - Sponsor Initiated (Eff. 9/1/1998 through 8/31/2003)
Amendment #1 (extends term: Effective 9/1/2003 through 12/31/2003)
Novartis Pharmaceuticals Corporation - Master Clinical Trial Agreement - Sponsor Initiated (Eff. 1/1/2004 through 12/31/2008)
Amendment #1 (Amended terms regarding Biological Samples) - 4/14/2009
Amendment #2 (Amended terms in 7G Confidential Information) - 11/27/2009
Amendment #3 (Extends term: effective 12/31/2008 to 4/30/2009) - 1/27/2009
Novartis Pharmaceuticals Corporation - Master Clinical Trial Agreement - Sponsor Initiated (Eff. 5/1/2009 through 4/30/2014)
Universal Clinical Trial Request Form Template (effective 3/12/2013)
Amendment #1 and HCI/HCP Contract Addendum (effective 6/5/2013)
Amendment #2 (effective 4/10/2014, extending term until 4/30/2019)
Amendment #3 (effective 1/3/2019, extending term until 8/31/2023)
Amendment #4 (explicitly deletes UTMDACC as Party to Master CTA - term ends 8/31/2023)
Novartis Pharmaceuticals Corporation - Master Clinical Trial Agreement - Investigator Initiated (Eff. 11/12/2014 --11/12/2019)
More Info on Novartis Pharmaceuticals Corporation- Master Clinical Trial Agreements
Fund Accounting Training: Module 3 Controller Fund Account Training: Module 3 More Info on Fund Accounting Training: Module 3
Fund Accounting Training: Module 6 Controller Fund Accounting Training: Module 6 More Info on Fund Accounting Training: Module 6
Fund Accounting Training: Module 1 Controller Fund Account Training: Module 1 More Info on Fund Accounting Training: Module 1
Fund Accounting Training: Module 4 Controller Fund Account Training: Module 4 More Info on Fund Accounting Training: Module 4
Fund Accounting Training: Module 7 Controller Fund Accounting Training: Module 7 More Info on Fund Accounting Training: Module 7
Fund Accounting Training: Module 2 Controller Fund Account Training: Module 2 More Info on Fund Accounting Training: Module 2
Fund Accounting Training: Module 5 Controller Fund Account Training: Module 5 More Info on Fund Accounting Training: Module 5